Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
349
datasets available to search
ShareScore release 0.9.0
Dataset results
349 results for “azithromycin”
Data set for the publication entitled "Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis"
<p>Set of files containing data used for microbiota analysis by 16S rRNA amplicon sequencing.</p> <p>The study cohort included patients with idiopathic pulmonary fibrosis from four centres in Switzerland, treated with azithromycin or placebo, sampled sequentially by oropharyngeal swab.</p> <p>This work is available in medRxiv and has been submitted</p>
Data from: The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease
<p><b>Background</b>: Selection for resistance to azithromycin (AZM) and other antibiotics such as tetracyclines and lincosamides remains a concern with long-term AZM use for treatment of chronic lung diseases (CLD). We investigated the impact of 48 weeks of AZM on the carriage and antibiotic resistance of common respiratory bacteria among children with HIV-associated CLD.</p> <p><b>Methods</b>: Nasopharyngeal (NP) swabs and sputa were collected at baseline, 48 and 72 weeks from participants with HIV-associated CLD randomised to receive weekly AZM or placebo for 48 weeks and followed post-intervention until 72 weeks. The primary outcomes were prevalence and antibiotic resistance of <i>Streptococcus pneumoniae</i> (SP), <i>Staphylococcus aureus </i>(SA), <i>Haemophilus influenzae </i>(HI), and <i>Moraxella catarrhalis </i>(MC) at these timepoints. Mixed-effects logistic regression and Fisher's exact test were used to compare carriage and resistance respectively.</p> <p><b>Results</b>: Of 347 (174 AZM, 173 placebo) participants (median age 15 years [IQR =13–18], females 49%),NP carriage was significantly lower in the AZM (n=159) compared to placebo (n=153) arm for SP (18% vs 41%, <i>p</i><0.001)<i>, </i>HI (7% vs 16%, p=0.01)<i>, </i>and MC (4% vs 11%, <i>p</i>=0.02); SP resistance to AZM (62% [18/29] vs 13%[8/63], <i>p</i><0.0001) or tetracycline (60%[18/29] vs 21%[13/63], <i>p</i><0.0001) were higher in the AZM arm. Carriage of SA resistant to AZM (91% [31/34] vs 3% [1/31],<i> p</i><0.0001), tetracycline (35% [12/34] vs 13% [4/31],<i> p</i>= 0.05) and clindamycin (79% [27/34] vs 3% [1/31],<i> p</i><0.0001) was also significantly higher in the AZM arm and persisted at 72 weeks. Similar findings were observed for sputa.</p> <p><b>Conclusions</b>: The persistence of antibiotic resistance and its clinical relevance for future infectious episodes requiring treatment needs further investigation.</p>
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
ClinicalTrials.gov study NCT04329832. IPD Sharing: NO. Countries: 1. Publications: 3.
Azithromycin-Prevention in Labor Use Study (A-PLUS)
ClinicalTrials.gov study NCT03871491. IPD Sharing: YES. Countries: 7. Publications: 44.
Data from: The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease
Open the record for dataset details and reuse information.
Dataset for Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance but rising azithromycin resistance
<p>This is Dataset used for Publication "Antimicrobial resistance of <em>Neisseria gonorrhoeae</em> in Germany: low levels of cephalosporin resistance but rising azithromycin resistance" and contains data on Information on performed Neisseria gonorrhoeae AMR tests in sentinel Laboratories as well as AMR testing in consiliary Laboratory.</p>
The Efficacy of Azithromycin in the Treatment of Influenza A infection: A Systematic Review
<p>Background:</p> <p>The WHO recommendation against the use of macrolides reflects the little low-quality evidence about the effect of azithromycin (AZ) on influenza A infection. Considering recent reports about AZ use despite the WHO's unfavorable recommendations, we aimed to test the evidence for the usage of AZ in the treatment of influenza A infection.</p> <p>Methods:</p> <p>Various online databases were searched till August 2023 and thorough text and evidence evaluation resulted in selecting 7 studies.</p> <p>Results:</p> <p>The selected reports included randomized control trials (two), cohort (three), case/control (one) studies, and one case report. Pooling of the results was unattainable due to the variability among studies in patient criteria, study outcomes, and study designs. Based on the limited reports with insufficient evidence, a recommendation for the use of AZ in the treatment regimen was not possible despite the associated reduction in inflammatory cytokines by AZ administration and the absence of significant adverse effects or mortality in hospital-admitted or ICU patients. While these findings support the current guidelines for the treatment of influenza A infection, the evidence behind these guidelines and treatment characteristics were illustrated.</p> <p>Conclusion:</p> <p>AZ shows a potential symptom improvement and pro-inflammatory laboratory indices in influenza A patients. Another positive aspect is the absence of complications associated with AZ administration to critically ill patients and acceptable prognosis. However, it is crucial to have more quality research on this matter that focuses on the indication of the use of AZ, and the timing of initiation, dosage, and duration of treatment while monitoring adverse events.</p>
Quantum chemical investigation of the predominant conformation of the antibiotic azithromycin in water and DMSO solutions: an integrated thermodynamic and NMR analysis
<p><span>Azithromycin (AZM) is a macrolide-type antibiotic used to prevent and treat serious infection</span><span>s (mycobacteria or MAC) that significantly inhibit bacterial growth. Knowledge of the predominant conformation in solution is of fundamental importance for advancing our understanding of the intermolecular interactions of AZM with biological targets. We report an extensive density functional theory (DFT) study of plausible AZM structures in solution considering implicit and explicit solvent effects. The best match between the experimental and theoretical nuclear magnetic resonance (NMR) profiles was used to assign the preferred conformer in solution, which was supported by the thermodynamic analysis. Among the 15 distinct AZM structures, conformer M14, having a short intramolecular C6-OH…N H-bond, is predicted to be dominant in water and DMSO solutions. The results indicated that the X-ray structure backbone is mostly conserved in solution, showing that large flexible molecules with several possible conformations may assume a preferential spatial orientation in solution, which is the molecular structure that ultimately interacts with biological targets.</span></p>
AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department
ClinicalTrials.gov study NCT04669288. IPD Sharing: NO. Countries: 1. Publications: 0.
Community Health Azithromycin Trial in Burkina Faso
ClinicalTrials.gov study NCT03676764. IPD Sharing: YES. Countries: 1. Publications: 9.
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
ClinicalTrials.gov study NCT02775617. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Neonates and Azithromycin, an Innovation in the Treatment of Children in Burkina Faso
ClinicalTrials.gov study NCT03682653. IPD Sharing: YES. Countries: 1. Publications: 5.
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
ClinicalTrials.gov study NCT00871494. IPD Sharing: Not stated. Countries: 1. Publications: 1.
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
ClinicalTrials.gov study NCT00322465. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT00325897. IPD Sharing: NO. Countries: 1. Publications: 9.
A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea
ClinicalTrials.gov study NCT04010539. IPD Sharing: YES. Countries: 6. Publications: 3.
Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
ClinicalTrials.gov study NCT01778634. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa
ClinicalTrials.gov study NCT01103063. IPD Sharing: Not stated. Countries: 5. Publications: 2.
Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children
ClinicalTrials.gov study NCT02707523. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trial II of Lung Protection With Azithromycin in the Preterm Infant
ClinicalTrials.gov study NCT00319956. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.